Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial

NCT01313494 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01313494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01313494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-month, Double-blind, Randomised, Multicenter, Multinational Trial to Investigate the Effect of 500 µg Roflumilast Tablets Once Daily Versus Placebo on Pulmonary Function in Patients With COPD. The ACROSS Trial
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
May 31, 2012
Enrollment
626 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

copd